Dohi Kenji, Satoh Kazue, Mihara Yuko, Nakamura Shunsuke, Miyake Yasuhumi, Ohtaki Hirokazu, Nakamachi Tomoya, Yoshikawa Toshikazu, Shioda Seiji, Aruga Tohru
Department of Emergency and Critical Care Medicine, School of Medicine, Showa University, Tokyo, Japan.
J Neurotrauma. 2006 Nov;23(11):1591-9. doi: 10.1089/neu.2006.23.1591.
Lipid peroxidation is caused by reactive oxygen species (ROS) and is involved in traumatic brain injury (TBI). Consequently, a therapeutic strategy for TBI may be to control lipid peroxidation. The only drug approved to date for blocking lipid peroxidation is edaravone (MCI-186), a novel free-radical scavenger shown to exert neuroprotective effects in acute ischemic stroke. Although edaravone scavenges hydroxyl and nitric oxide radicals, its effect on alkoxyl radicals (OR-), which also contribute to lipid peroxidation, is unknown. To date, the study of free radicals in blood has been severely hampered by technical difficulties in their detection. We used an in vitro and ex vivo electron spin resonance (ESR) method employing 5,5-dimethyl-1-pyrroline-N-oxide as a spin trap to investigate whether edaravone can scavenge OR-. By mixing either methemoglobin or human blood with tert-butyl hydroperoxide, we found that this technique can detect OR- generated in vitro. We also found that generated OR- can be completely absorbed by administration of edaravone in vitro (400 microM). Analysis of jugular venous blood collected from 17 TBI patients immediately before and 20 minutes after the administration of edaravone (30 mg, i.v.) revealed higher OR- levels in the untreated patients blood than in normal control blood samples. However, treatment with edaravone suppressed these OR- levels by 24.6% (radical intensity = 71.1 +/- 5.2-53.6 +/- 5.2; p < 0.01). Thus, edaravone can scavenge OR- and significantly reduce levels of these radicals in TBI patients. The novel ex vivo ESR method described here provides a valuable clinical measure of oxidative stress.
脂质过氧化由活性氧(ROS)引起,与创伤性脑损伤(TBI)有关。因此,TBI的一种治疗策略可能是控制脂质过氧化。迄今为止,唯一被批准用于阻断脂质过氧化的药物是依达拉奉(MCI - 186),这是一种新型自由基清除剂,已证明在急性缺血性卒中中具有神经保护作用。尽管依达拉奉可清除羟基和一氧化氮自由基,但其对同样导致脂质过氧化的烷氧基自由基(OR-)的作用尚不清楚。迄今为止,血液中自由基的研究因检测技术困难而受到严重阻碍。我们使用体外和离体电子自旋共振(ESR)方法,采用5,5 - 二甲基 - 1 - 吡咯啉 - N - 氧化物作为自旋捕集剂,研究依达拉奉是否能清除OR-。通过将高铁血红蛋白或人血与叔丁基过氧化氢混合,我们发现该技术可检测体外产生的OR-。我们还发现,体外给予依达拉奉(400 microM)可完全吸收产生的OR-。对17例TBI患者在静脉注射依达拉奉(30 mg)前即刻和给药后20分钟采集的颈静脉血进行分析,结果显示未治疗患者血液中的OR-水平高于正常对照血样。然而,依达拉奉治疗使这些OR-水平降低了24.6%(自由基强度 = 71.1±5.2 - 53.6±5.2;p < 0.01)。因此,依达拉奉可清除OR-并显著降低TBI患者体内这些自由基的水平。本文所述的新型离体ESR方法为氧化应激提供了一种有价值的临床检测手段。